SCHEMBL26317513

SCHEMBL26317513

CC(C)OC(=O)N1CCN(C(=O)OC(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
GPR119 Q8TDV5 7/20 0.40
HRH2 P25021 1/20 0.40
HRH1 P35367 1/20 0.40
PDK2 Q15119 1/20 0.40
FAAH O00519 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GAA P10253 1/20 0.37
P2RX4 Q99571 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
BCHE P06276 1/20 0.36
KDM1A O60341 1/20 0.36
PIK3CD O00329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12184259 0.91 PIK3CD (0.48) TSHRGPR119HRH2HRH1PDK2
SCHEMBL10053019 0.91 CYP1A2 (0.48) TSHRGPR119HRH2HRH1ALDH1A1
SCHEMBL2654623 0.90 TSHR (0.40) TSHRGPR119HRH2HRH1PDK2
SCHEMBL5412873 0.90 ALDH1A1 (0.42) TSHRGPR119FAAHALDH1A1POLB
SCHEMBL24715746 0.89 GPR119 (0.36) TSHRGPR119HRH2HRH1PDK2
SCHEMBL17244903 0.89 HRH3 (0.43)
SCHEMBL18630111 0.89 GPR119 (0.39) TSHRGPR119HRH2HRH1PDK2
SCHEMBL12283406 0.88 ALDH1A1 (0.45) TSHRGPR119ALDH1A1POLBHTT
SCHEMBL12282193 0.88 ALDH1A1 (0.45) TSHRGPR119ALDH1A1POLBHTT
SCHEMBL390019 0.88 ALDH1A1 (0.45) TSHRGPR119ALDH1A1POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2023-08-22 US disclosed
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2023-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms CRBN, CD4, CD74 TSHR 4168/4885GPR119 1593/4885HRH2 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.